Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -194787.38% is 245% below its 5-year average of -56466.14%, near the low end of its 5-year range (-194787.38%–-8918.67%).
82.81% below its 12-month average of -106551.87%.
Reported quarterly EBITDA margin; no daily interpolation. Q1 FY2027 (2026-07-31): -138312.48%.
EBITDA MARGIN
-194787.38%
EBITDA MARGIN AVG TTM
-106551.87%
EBITDA MARGIN AVG 3Y
-68915.78%
EBITDA MARGIN AVG 5Y
-56466.14%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-82.81%
CURRENT VS 3Y AVG
-182.65%
CURRENT VS 5Y AVG
-244.96%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
HeartSciences Inc.
Market Cap
$8.14M
EBITDA Margin
-194787.38%
TTM Avg
-106551.87%
3Y Avg
-68915.78%
5Y Avg
-56466.14%
Market Cap
$8.01M
EBITDA Margin
-33055.56%
TTM Avg
-18473.68%
3Y Avg
-9547.23%
5Y Avg
-12604.39%
Market Cap
$8.31M
EBITDA Margin
-65.39%
TTM Avg
-49.20%
3Y Avg
-36.51%
5Y Avg
-25.14%
Market Cap
$7.92M
EBITDA Margin
-951.52%
TTM Avg
-1801.56%
3Y Avg
-1801.56%
5Y Avg
-1801.56%
Market Cap
$7.92M
EBITDA Margin
-638.49%
TTM Avg
-11234.29%
3Y Avg
-10030.31%
5Y Avg
-9704.67%
Market Cap
$7.87M
EBITDA Margin
-144973.96%
TTM Avg
-73136.05%
3Y Avg
-36678.29%
5Y Avg
-29395.87%
Market Cap
$8.73M
EBITDA Margin
-334.15%
TTM Avg
-180.95%
3Y Avg
-121.99%
5Y Avg
-121.99%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| HeartSciences Inc. (HSCS) | $8.14M | -194787.38% | -106551.87% | -68915.78% | -56466.14% |
| CNS Pharmaceuticals, Inc. (CNSP)vs › | $8.01M | N/A | N/A | N/A | N/A |
| GT Biopharma, Inc. (GTBP)vs › | $8.01M | -33055.56% | -18473.68% | -9547.23% | -12604.39% |
| Healthcare Triangle, Inc. (HCTI)vs › | $8.31M | -65.39% | -49.20% | -36.51% | -25.14% |
| Aprea Therapeutics, Inc. (APRE)vs › | $7.92M | -951.52% | -1801.56% | -1801.56% | -1801.56% |
| Traws Pharma, Inc. (TRAW)vs › | $7.92M | -638.49% | -11234.29% | -10030.31% | -9704.67% |
| ENDRA Life Sciences Inc. (NDRA)vs › | $7.87M | -144973.96% | -73136.05% | -36678.29% | -29395.87% |
| DataMEDS AI, Inc. (MEDS)vs › | $8.73M | -334.15% | -180.95% | -121.99% | -121.99% |
| Quince Therapeutics, Inc. (QNCX)vs › | $7.52M | N/A | N/A | N/A | N/A |
| Advanced Biomed Inc. Common Stock (ADVB)vs › | $9.09M | N/A | N/A | N/A | N/A |
Gross Margin
N/A
EBITDA Margin
-194787.4%
Operating Margin
N/A
Net Margin
N/A
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-07-31 | -138312.48% |
| 2025-10-31 | -84372.39% |
| 2025-07-31 | -96970.74% |
| 2025-04-30 | -43428.48% |
| 2024-01-31 | -10351.45% |
| 2023-10-31 | -40059.15% |
| 2023-01-31 | -66791.69% |
| 2022-07-31 | -44490.16% |
| 2022-04-30 | -47512.99% |
| 2022-01-31 | -39919.38% |
| 2021-07-31 | -8918.67% |
| 2021-04-30 | -5210.61% |
